BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16433041)

  • 1. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice.
    Papagiannaros A; Hatziantoniou S; Lelong-Rebel IH; Papaioannou GT; Dimas K; Demetzos C
    In Vivo; 2006; 20(1):129-35. PubMed ID: 16433041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.
    Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C
    Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
    Papagiannaros A; Bories C; Demetzos C; Loiseau PM
    Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines.
    Papagiannaros A; Dimas K; Papaioannou GT; Demetzos C
    Int J Pharm; 2005 Sep; 302(1-2):29-38. PubMed ID: 16099117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.
    Williams SS; Alosco TR; Mayhew E; Lasic DD; Martin FJ; Bankert RB
    Cancer Res; 1993 Sep; 53(17):3964-7. PubMed ID: 8358724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
    Sakakibara T; Chen FA; Kida H; Kunieda K; Cuenca RE; Martin FJ; Bankert RB
    Cancer Res; 1996 Aug; 56(16):3743-6. PubMed ID: 8706018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
    Lindner LH; Hossann M; Vogeser M; Teichert N; Wachholz K; Eibl H; Hiddemann W; Issels RD
    J Control Release; 2008 Jan; 125(2):112-20. PubMed ID: 18022271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and development of liposomes incorporating a bioactive labdane-type diterpene. In vitro growth inhibiting and cytotoxic activity against human cancer cell lines.
    Matsingou C; Dimas K; Demetzos C
    Biomed Pharmacother; 2006 May; 60(4):191-9. PubMed ID: 16675195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
    Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
    Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts.
    Hatziantoniou S; Dimas K; Georgopoulos A; Sotiriadou N; Demetzos C
    Pharmacol Res; 2006 Jan; 53(1):80-7. PubMed ID: 16253514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.
    Rahman A; White G; More N; Schein PS
    Cancer Res; 1985 Feb; 45(2):796-803. PubMed ID: 3967247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.
    Giuliani FC; Kaplan NO
    Cancer Res; 1980 Dec; 40(12):4682-7. PubMed ID: 7438099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin.
    Xu Y; Choi J; Hylander B; Sen A; Evans SS; Kraybill WG; Repasky EA
    Int J Hyperthermia; 2007 Sep; 23(6):513-27. PubMed ID: 17952765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.